Sekar Kathiresan - Jul 19, 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role: Chief Executive Officer, Director
Signature: /s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan
Stock symbol: VERV
Transactions as of: Jul 19, 2022
Transactions value $: -$1,425,500
Form type: 4
Date filed: 7/21/2022, 05:00 PM
Previous filing: Jul 15, 2022
Next filing: Jul 27, 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VERV	Common Stock	Options Exercise	$69.5K	+50K	+15.73%	$1.39^*	368K	Jul 19, 2022	Direct
transaction	VERV	Common Stock	Sale	-$1.5M	-50K	-13.59%	$29.90	318K	Jul 19, 2022	Direct	F1
holding	VERV	Common Stock						241K	Jul 19, 2022	Kathiresan Family 2021 Irrevocable Trust
holding	VERV	Common Stock						81K	Jul 19, 2022	Sekar Kathiresan 2021 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VERV	Stock Option (right to buy)	Options Exercise	$0	-50K	-18.7%	$0.00	217K	Jul 19, 2022	Common Stock	50K	$1.39	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022.
F2	The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023.